(Q73401694)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

primary biliary cholangitis

3 November 2019

main subject

0 references

author name string

Angulo P

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Jorgensen RA

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Keach JC

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Dickson ER

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Smith C

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Lindor KD

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

0 references

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

318-323

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Oral budesonide for treatment of autoimmune chronic active hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Factors of prognostic importance in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Ultrastructural and immunohistochemical studies of the intrahepatic peribiliary capillary plexus in normal livers and extrahepatic biliary obstruction in human beings

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310209

7 January 2021

Identifiers

DOI

10.1002/HEP.510310209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10655252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference